{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T11:06:52Z","timestamp":1785323212008,"version":"3.55.0"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.critrevonc.2019.01.008","type":"journal-article","created":{"date-parts":[[2019,1,27]],"date-time":"2019-01-27T02:09:00Z","timestamp":1548554940000},"page":"76-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Biomarkers in Non-Schistosomiasis-related squamous cell carcinoma of the urinary bladder: A review"],"prefix":"10.1016","volume":"135","author":[{"given":"Manuel Caitano","family":"Maia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2363-8707","authenticated-orcid":false,"given":"Aaron","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Salah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2019.01.008_bib0005","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/j.1464-410X.2011.10357.x","article-title":"Survival after radical cystectomy of non-bilharzial squamous cell carcinoma vs urothelial carcinoma: a competing-risks analysis","volume":"109","author":"Abdollah","year":"2012","journal-title":"BJU Int."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0010","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1756-9966-28-27","article-title":"Tumor markers of bladder cancer: the schistosomal bladder tumors versus non-schistosomal bladder tumors","volume":"28","author":"Abdulamir","year":"2009","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0015","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.urology.2006.08.1107","article-title":"Nonurothelial cancer of the bladder","volume":"69","author":"Abol-Enein","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0020","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","article-title":"Bladder cancer incidence and mortality: a global overview and recent trends","volume":"71","author":"Antoni","year":"2017","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0025","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1200\/JCO.2016.71.6795","article-title":"Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a Multicenter, Phase Ib Study","volume":"35","author":"Apolo","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0030","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.6_suppl.425","article-title":"Differences in survival among non-urothelial bladder cancers: analyses of SEER 1988\u20132008","volume":"36","author":"Aragon-Ching","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0035","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.humpath.2003.10.006","article-title":"Muscle invasive schistosomal squamous cell carcinoma of the urinary bladder: frequency and prognostic significance of p53, BCL-2, HER2\/neu, and proliferation (MIB-1)","volume":"35","author":"Badr","year":"2004","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0040","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdw435.25","article-title":"Pembrolizumab (pembro) as first-line therapy for advanced\/unresectable or metastatic urothelial cancer: preliminary results from the phase 2 KEYNOTE-052 study","volume":"27","author":"Balar","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0045","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0050","doi-asserted-by":"crossref","first-page":"71429","DOI":"10.18632\/oncotarget.12198","article-title":"Fibroblast growth factor receptor (FGFR) alterations in squamous differentiated bladder cancer: a putative therapeutic target for a small subgroup","volume":"7","author":"Baldia","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0055","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0060","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.6_suppl.410","article-title":"Two-year follow-up from the phase 3 KEYNOTE-045 trial of pembrolizumab (pembro) vs investigator\u2019s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC)","volume":"36","author":"Bellmunt","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0065","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1158\/1078-0432.CCR-04-2409","article-title":"Bladder cancer outcome and subtype classification by gene expression","volume":"11","author":"Blaveri","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0070","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0075","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","author":"Cancer Genome Atlas Research, N","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0080","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1002\/1522-2683(20000601)21:11<2115::AID-ELPS2115>3.0.CO;2-K","article-title":"Bladder squamous cell carcinoma biomarkers derived from proteomics","volume":"21","author":"Celis","year":"2000","journal-title":"Electrophoresis"},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0085","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.5489\/cuaj.1195","article-title":"Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer","volume":"3","author":"Chalasani","year":"2009","journal-title":"Can. Urol. Assoc. J."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0090","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0095","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nrurol.2014.129","article-title":"Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer","volume":"11","author":"Choi","year":"2014","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0100","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0302-2838(03)00416-0","article-title":"Malignant non-urothelial neoplasms of the urinary bladder: a review","volume":"44","author":"Dahm","year":"2003","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0105","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1073\/pnas.1318376111","article-title":"Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology","volume":"111","author":"Damrauer","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0110","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.clinbiochem.2004.09.004","article-title":"HER2\/neu expression in bladder cancer: relationship to cell cycle kinetics","volume":"38","author":"Eissa","year":"2005","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0115","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1177\/172460080301800406","article-title":"Prognostic value of p53 and MDM2 expression in bilharziasis-associated squamous cell carcinoma of the urinary bladder","volume":"18","author":"El-Kenawy Ael","year":"2003","journal-title":"Int. J. Biol. Markers"},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0120","doi-asserted-by":"crossref","first-page":"170","DOI":"10.5301\/JBM.2008.1487","article-title":"Prognostic value of carcinoma-associated antigen MK-1 in urinary bladder carcinoma","volume":"21","author":"El-Meghawry El-Kenawy","year":"2006","journal-title":"Int. J. Biol. Markers"},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0125","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0002-9440(10)64956-5","article-title":"DNA copy number changes in Schistosoma-associated and non-Schistosoma-associated bladder cancer","volume":"156","author":"El-Rifai","year":"2000","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0130","first-page":"421","article-title":"The changing patterns of bladder cancer in Egypt over the past 26 years","volume":"19","author":"Felix","year":"2008","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0135","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0140","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0002-9440(10)63699-1","article-title":"Down-regulation of nitric oxide synthase-2 and cyclooxygenase-2 pathways by p53 in squamous cell carcinoma","volume":"163","author":"Gallo","year":"2003","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0145","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.urology.2006.10.029","article-title":"Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract","volume":"69","author":"Galsky","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0150","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0022-5347(17)47119-9","article-title":"Randomized trial of cystectomy with or without preoperative radiotherapy for carcinoma of the bilharzial bladder","volume":"134","author":"Ghoneim","year":"1985","journal-title":"J. Urol."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0155","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0022-5347(01)64487-2","article-title":"Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases","volume":"158","author":"Ghoneim","year":"1997","journal-title":"J. Urol."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0160","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.humpath.2009.03.005","article-title":"Squamous cell carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical study of 16 cases","volume":"40","author":"Guo","year":"2009","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0165","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0022-5347(05)66332-X","article-title":"Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, e-cadherin, epidermal growth factor receptor and c-erbb-2","volume":"165","author":"Haitel","year":"2001","journal-title":"J. Urol."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0170","first-page":"733","article-title":"Expression of cytokeratin 7, 20, 14 in urothelial carcinoma and squamous cell carcinoma of the Egyprian urinary bladder cancer","volume":"44","author":"Hammam","year":"2014","journal-title":"J. Egypt. Soc. Parasitol."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0175","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.aju.2015.01.004","article-title":"The clinical significance of HER2 protein amplification\/expression in urinary bladder lesion","volume":"13","author":"Hammam","year":"2015","journal-title":"Arab. J. Urol."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0180","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1002\/cncr.23420","article-title":"Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin","volume":"112","author":"Higano","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0185","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/S0022-5347(05)65104-X","article-title":"Bladder tumor producing granulocyte colony-stimulating factor and parathyroid hormone related protein","volume":"167","author":"Hirasawa","year":"2002","journal-title":"J. Urol."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0190","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.2001.19.9.2527","article-title":"Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer","volume":"19","author":"Hussain","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0195","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1126\/science.1226344","article-title":"Genome sequencing identifies a basis for everolimus sensitivity","volume":"338","author":"Iyer","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0200","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","article-title":"Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer","volume":"366","author":"James","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0205","first-page":"277","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0210","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/cncr.22853","article-title":"Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of The University of Texas M D Anderson Cancer Center experience","volume":"110","author":"Kassouf","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0215","first-page":"3865","article-title":"The outcome of patients with advanced pure squamous or mixed squamous and transitional urothelial carcinomas following platinum-based chemotherapy","volume":"26","author":"Kastritis","year":"2006","journal-title":"Anticancer Res."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0220","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0959-8049(00)00079-4","article-title":"A phase II study of gemcitabine plus cisplatin chemotherapy in advanced bilharzial bladder carcinoma","volume":"36","author":"Khaled","year":"2000","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0225","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.6_suppl.490","article-title":"Clinical outcomes of patients with histologic variants of urothelial carcinoma treated with tetra-modality bladder-sparing protocol incorporating consolidative partial cystectomy","volume":"36","author":"Kijima","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0230","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0235","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1097\/PAS.0b013e31805c9cd9","article-title":"Squamous cell carcinoma of the bladder: a clinicopathologic analysis of 45 cases","volume":"31","author":"Lagwinski","year":"2007","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0240","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0245","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S0022-5347(17)49366-9","article-title":"Incidence of squamous cell carcinoma in patients with long-term catheter drainage","volume":"133","author":"Locke","year":"1985","journal-title":"J. Urol."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0250","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.6_suppl.411","article-title":"Erdafitinib (ERDA; JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRa): phase 2 continuous versus intermittent dosing","volume":"36","author":"Loriot","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0255","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4111\/kju.2015.56.1.31","article-title":"Expression of survivin in squamous cell carcinoma and transitional cell carcinoma of the urinary bladder: a comparative immunohistochemical study","volume":"56","author":"Makboul","year":"2015","journal-title":"Korean J. Urol."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0260","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1464-410X.2005.05327.x","article-title":"Non-transitional cell bladder carcinomas","volume":"95","author":"Manunta","year":"2005","journal-title":"BJU Int."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0265","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.aju.2016.07.001","article-title":"Squamous cell carcinoma of the urinary bladder: systematic review of clinical characteristics and therapeutic approaches","volume":"14","author":"Martin","year":"2016","journal-title":"Arab. J. Urol."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0270","article-title":"Analyses of publicly available genomics resources define FGF-2-expressing bladder carcinomas as EMT-prone, proliferative tumors with low mutation rates and high expression of CTLA-4, PD-1 and PD-L1","volume":"2","author":"McNiel","year":"2017","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0275","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1464-410X.2012.11720.x","article-title":"Phase II study of everolimus in metastatic urothelial cancer","volume":"112","author":"Milowsky","year":"2013","journal-title":"BJU Int."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0280","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1016\/j.ejca.2014.10.013","article-title":"Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma","volume":"50","author":"Milowsky","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0285","first-page":"8143","article-title":"Comparison of structural genetics of non-schistosoma-associated squamous cell carcinoma of the urinary bladder","volume":"8","author":"Molitor","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0290","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","author":"Motzer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0295","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1200\/JCO.2016.67.2048","volume":"35","author":"Nogova","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0300","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.juro.2015.06.115","article-title":"Second line chemotherapy for advanced and metastatic urothelial carcinoma: vinflunine and beyond-A comprehensive review of the current literature","volume":"195","author":"Oing","year":"2016","journal-title":"J. Urol."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0305","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1615\/JEnvironPatholToxicolOncol.v31.i3.20","article-title":"CD10 and E-cad expression in urinary bladder urothelial and squamous cell carcinoma","volume":"31","author":"Omran","year":"2012","journal-title":"J. Environ. Pathol. Toxicol. Oncol."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0310","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/(SICI)1522-2683(19990201)20:2<349::AID-ELPS349>3.0.CO;2-B","article-title":"Psoriasin (S100A7): a putative urinary marker for the follow-up of patients with bladder squamous cell carcinomas","volume":"20","author":"Ostergaard","year":"1999","journal-title":"Electrophoresis"},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0315","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.4517","article-title":"Efficacy of BGJ398, a fibroblast growth factor receptor (FGFR) 1-3 inhibitor, in patients (pts) with previously treated advanced\/metastatic urothelial carcinoma (mUC) with FGFR3 alterations","volume":"34","author":"Pal","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0320","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0090-4295(01)01495-9","article-title":"Transitional cell carcinoma in patients with spinal cord injury: a high risk malignancy?","volume":"59","author":"Pannek","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0325","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1016\/S0022-5347(05)64272-3","article-title":"Racial variation in the incidence of squamous cell carcinoma of the bladder in the United States","volume":"168","author":"Porter","year":"2002","journal-title":"J. Urol."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0330","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1200\/JCO.2015.66.3468","article-title":"Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1\/2-positive metastatic bladder cancer","volume":"35","author":"Powles","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0335","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","author":"Powles","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0340","doi-asserted-by":"crossref","first-page":"e172411","DOI":"10.1001\/jamaoncol.2017.2411","article-title":"Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1\/2 open-label study","author":"Powles","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0345","first-page":"37","article-title":"Radiation management of squamous cell carcinoma of the bladder","volume":"23","author":"Prempree","year":"1984","journal-title":"Acta Radiol.: Oncol."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0350","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0090-4295(98)00626-8","article-title":"Numerical chromosomal aberrations in muscle invasive squamous cell and transitional cell cancer of the urinary bladder: an alternative to classic prognostic indicators?","volume":"53","author":"Pycha","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0355","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/ijc.2910620302","article-title":"Molecular events underlying schistosomiasis-related bladder cancer","volume":"62","author":"Ramchurren","year":"1995","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0360","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0365","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.biopha.2012.10.019","article-title":"Is there a correlation between HPV and urinary bladder carcinoma?","volume":"67","author":"Shaker","year":"2013","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0370","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0375","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1464-410X.2004.04588.x","article-title":"Squamous cell carcinoma of the bladder: pathology, diagnosis and treatment","volume":"93","author":"Shokeir","year":"2004","journal-title":"BJU Int."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0380","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.6_suppl.498","article-title":"Prognostic impact of percentage of squamous differentiation in patients with nonbilharzial squamous cell carcinoma and transitional cell carcinoma treated with radical cystectomy","volume":"36","author":"Slim","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2019.01.008_bib0385","first-page":"266","article-title":"Safety and activity of the pan\u2013fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients with advanced urothelial carcinoma","volume":"27","author":"Soria","year":"2016","journal-title":"Ann. Oncol."},{"issue":"417","key":"10.1016\/j.critrevonc.2019.01.008_bib0390","first-page":"e411","article-title":"Lymphovascular invasion is associated with oncologic outcomes following radical cystectomy for squamous cell carcinoma of the urinary bladder","volume":"34","author":"Spradling","year":"2016","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0395","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S0022-5347(17)36156-6","article-title":"Squamous cell carcinoma of the bladder associated with cyclophosphamide therapy for Wegener\u2019s granulomatosis: a report of 2 cases","volume":"149","author":"Stein","year":"1993","journal-title":"J. Urol."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0400","doi-asserted-by":"crossref","first-page":"10911","DOI":"10.1074\/jbc.274.16.10911","article-title":"Inhibition of cyclooxygenase-2 gene expression by p53","volume":"274","author":"Subbaramaiah","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0405","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0022-5347(17)39857-9","article-title":"Preoperative irradiation and radical cystectomy for stages T2 and T3 squamous cell carcinoma of the bladder","volume":"143","author":"Swanson","year":"1990","journal-title":"J. Urol."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0410","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-2490-2-8","article-title":"Problems in early diagnosis of bladder cancer in a spinal cord injury patient: report of a case of simultaneous production of granulocyte colony stimulating factor and parathyroid hormone-related protein by squamous cell carcinoma of urinary bladder","volume":"2","author":"Vaidyanathan","year":"2002","journal-title":"BMC Urol."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0415","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-13-0353","article-title":"Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib","author":"Wagle","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0420","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/sc.2013.33","article-title":"Bladder cancer in individuals with spinal cord injuries","volume":"51","author":"Welk","year":"2013","journal-title":"Spinal Cord"},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0425","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1046\/j.1464-410x.2001.02230.x","article-title":"Human papillomaviruses 6\/11, 16\/18 and 31\/33\/51 are not associated with squamous cell carcinoma of the urinary bladder","volume":"88","author":"Westenend","year":"2001","journal-title":"BJU Int."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0430","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1146\/annurev.physiol.60.1.431","article-title":"The physiology of parathyroid hormone-related protein: an emerging role as a developmental factor","volume":"60","author":"Wysolmerski","year":"1998","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0435","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1464-410X.2010.09854.x","article-title":"Bilharzial vs non-bilharzial related bladder cancer: pathological characteristics and value of cyclooxygenase-2 expression","volume":"108","author":"Youssef","year":"2011","journal-title":"BJU Int."},{"key":"10.1016\/j.critrevonc.2019.01.008_bib0440","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.juro.2014.08.109","article-title":"Utility of biomarkers in the prediction of oncologic outcome after radical cystectomy for squamous cell carcinoma","volume":"193","author":"Youssef","year":"2015","journal-title":"J. Urol."},{"issue":"111","key":"10.1016\/j.critrevonc.2019.01.008_bib0445","first-page":"e111","article-title":"Role of fibroblast growth factor in squamous cell carcinoma of the bladder: prognostic biomarker and potential therapeutic target","volume":"33","author":"Youssef","year":"2015","journal-title":"Urol. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842818301811?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842818301811?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:28:59Z","timestamp":1760902139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842818301811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":89,"alternative-id":["S1040842818301811"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2019.01.008","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarkers in Non-Schistosomiasis-related squamous cell carcinoma of the urinary bladder: A review","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2019.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}